Overview

Landiolol in Postoperative Atrial Fibrillation

Status:
Completed
Trial end date:
2019-12-04
Target enrollment:
Participant gender:
Summary
Postoperative atrial fibrillation is a common complication after cardiac surgery and is associated with an elevation of morbidity and mortality. The recommended treatment includes heart rate control with a beta blocker. Landiolol is a new-generation beta-blocker with favourable pharmacologic properties making an interesting drug to treat postoperative atrial fibrillation. However, Landiolol micro and macrocirculatory effects in the setting of atrial fibrillation are yet to describe. The aim of this study is to describe microcirculatory effects of incremental doses of landiolol in postoperative atrial fibrillation compared to a placebo. Our hypothesis is Landiolol will improve microcirculation disorders.
Phase:
Phase 3
Details
Lead Sponsor:
Hospices Civils de Lyon
Treatments:
Landiolol